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Abstract
Background: Single-arm trials are currently an accepted study design to investigate 
the efficacy of novel therapies (NT) in non-muscle invasive bladder cancer (NMIBC) 
unresponsive to intravesical Bacillus Calmette-Guérin (BCG) immunotherapy as 
randomized controlled trials are either unfeasible (comparator: early radical cystec-
tomy; ERC), or unethical (comparator: placebo). To guide the design of such sin-
gle-arm trials, expert groups published recommendations for clinically meaningful 
outcomes. The aim of this study was to quantitatively verify the appropriateness of 
these recommendations.
Methods: We used a discrete event simulation framework in combination with a su-
percomputer to find the required efficacy at which a NT can compete with ERC when 
it comes to quality-adjusted life expectancy (QALE). In total, 24 different efficacy 
thresholds (including the recommendations) were investigated.
Results: After ascertaining face validity with content experts, repeated verification, 
external validation, and calibration we considered our model valid. Both recommen-
dations rarely showed an incremental benefit of the NT over ERC. In the most op-
timistic scenario, an increase in the IBCG recommendation by 10% and an increase 
in the FDA/AUA recommendation by 5% would yield results at which a NT could 
compete with ERC from a QALE perspective.
Conclusions: This simulation study demonstrated that the current recommendations 
regarding clinically meaningful outcomes for single-arm trials evaluating the effi-
cacy of NT in BCG-unresponsive NMIBC may be too low. Based on our quantitative 
approach, we propose increasing these thresholds to at least 45%-55% at 6 months 
and 35% at 18-24 months (complete response rates/recurrence-free survival) to pro-
mote the development of clinically truly meaningful NT.
K E Y W O R D S
BCG vaccine, clinical trial, phase ii, computer simulation, cystectomy, decision support techniques, 
organ sparing treatments, urinary bladder neoplasms
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1 |  INTRODUCTION
Patients with non-muscle invasive bladder cancer (NMIBC) 
unresponsive to intravesical Bacillus Calmette-Guérin (BCG) 
immunotherapy pose a clinical dilemma1: On the one hand, 
surgical tumor extirpation before progression to muscle-in-
vasive disease (ie, early radical cystectomy; ERC) is the sole 
standard therapy.1,2 However, this procedure is not only asso-
ciated with considerable perioperative mortality and morbid-
ity3 but also leads in most patients to a substantial decrease 
in quality of life.4 On the other hand, several bladder-spar-
ing novel therapies ranging from systemic immune check-
point blockade to photodynamic therapy have been proposed 
during the last years.1 Although these modalities can poten-
tially delay or even avoid ERC and hence preserve quality of 
life, they all come at the cost of inferior cancer control.
Considering the infeasibility of a randomized controlled 
trial comparing a specific novel therapy to ERC, the unavail-
ability of an effective comparator arm besides ERC, and the 
fact that it is unethical to use placebo controls in this set-
ting, the United States Food and Drug Administration (FDA) 
currently allows single-arm phase II trials for the assessment 
and registration of novel therapies in BCG-unresponsive 
NMIBC.5 Two recommendations regarding clinically mean-
ingful outcomes of such single-arm trials have been published 
so far: The International Bladder Cancer Group (IBCG) con-
siders complete response rates (carcinoma in situ; CIS) and 
recurrence-free rates (papillary tumors) of 50% at 6 months, 
30% at 12  months, and 25% at 18  months as clinically 
meaningful6 while a public workshop of the FDA and the 
American Urological Association (AUA) proposed 40%-50% 
at 6 months and 30% at 18-24 months (regardless if CIS or 
papillary tumor).7 Although both recommendations are prod-
ucts of intensive discussions among renowned experts, they 
are not purely based on quantitative evidence. Therefore, the 
aim of this study was to quantitatively verify the two recom-
mendations using a decision-analytic approach. Specifically, 
we used a simulation framework in combination with the in-
frastructure of a supercomputer to find the required efficacy 
at which a novel therapy can compete with ERC when it 
comes to quality-adjusted life expectancy.
2 |  METHODS
We built a discrete event simulation model in the statistical 
programing language R (R Core Team, Vienna, Austria). The 
simulation-specific framework was implemented by the sim-
mer package, a package specifically developed for discrete 
event simulations in R.8 Computations were performed on 
the Niagara supercomputer using a 640-core setup (SciNet 
HPC Consortium, Toronto ON, Canada).9,10 We followed the 
methodology described by Caro et al11 during model devel-
opment, validation, calibration, and analysis. The reporting 
of this study is in accordance with the guidelines published 
by the Society of Medical Decision Making.12 The Appendix 
S1 provides an in-depth description of the model.
2.1 | Simulation setting and strategies
We simulated different management strategies (including 
ERC and novel therapies) in a cohort of BCG-unresponsive 
NMIBC patients from the date of diagnosis of BCG-
unresponsive disease to the date of death. Age, gender, and 
tumor type (ie, CIS, Ta, Ta + CIS, T1, T1 + CIS) were sam-
pled based on recent trials in the BCG-unresponsive NMIBC 
setting.13,14 The strategy “ERC” consisted of immediate 
performance of ERC and potential adjuvant chemotherapy 
(based on local tumor extension, nodal status, and patient 
preference). As the term “novel therapy” stands for various 
treatment modalities that differ with regard to route of admin-
istration, duration and adverse effects, we decided to repre-
sent “novel therapy” by three distinct strategies (ie, systemic, 
low-intensity intravesical, high-intensity intravesical) that 
share several characteristics as described in Table 1.
Regardless of the specific type of novel therapy, all of the 
strategies involving novel therapy start with the initial treatment 
T A B L E  1  Characterization of the three types of novel therapies that were all simulated as distinct strategies
Type of novel therapy Systemic Low-intensity intravesical High-intensity intravesical
Description Immune checkpoint blockade or 
targeted therapy
Local therapy with a low 
toxicity compound, usually 
several applications
Local therapy with a high 
toxicity compound, usually a 
single application
Typical example Pembrolizumab (every 3 weeks 
for 2 years)
rAd–IFNa/Syn3 (4 applications 
distributed over 1 year)
Photodynamic therapy (single 
application)
Assumed durationa 2 years 1 year 3 months
Burden of systemic adverse effects Moderate/high Low Low
Burden of urogenital adverse effects Low Low/moderate Moderate/high
aThis duration reflects the whole active treatment phase during which we assumed the disutility of the novel therapy to be present. 
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application. Patients are then followed with cystoscopy and cy-
tology (intervals of 3 months in year 1 and 2, 6 months in years 
3 and 4, 12 months after year 4) until they die from a cause un-
related to bladder cancer or until they experience failure of the 
novel therapy. In the event of treatment failure, patients receive 
a standardized workup (transurethral resection/bladder biopsy 
and cross-sectional imaging) before they proceed to radical 
cystectomy. Depending on the staging results, patients might 
be offered neoadjuvant chemotherapy (in the presence of 
muscle-invasive disease) or the surgeon might cancel radical 
cystectomy (in the presence of metastatic progression). From 
the time point of radical cystectomy, patients of strategies in-
volving novel therapies share a common trajectory with the 
patients of the strategy “ERC” and can therefore also receive 
adjuvant chemotherapy (depending on local tumor extension, 
nodal status, patient preference, and under the provision that 
no neoadjuvant chemotherapy was given). In the post-cystec-
tomy phase, patients can die due to causes unrelated to blad-
der-cancer or they might experience disease recurrence. In the 
event of disease recurrence, they receive maximal palliative 
treatment until they die from bladder cancer.
2.2 | Simulation logic
A discrete event simulation is structured around events. Events 
can represent clinical events such as cystoscopy/cytology visit 
or death but also biological events such as progression to 
muscle-invasive disease or development of distant metastases. 
Based on specified time to event distributions, each patient 
gets a distinct set of event times. During the actual simula-
tion, a patient always experiences the event that is next in time 
(eg, start of adjuvant chemotherapy is experienced before 
recurrence if timerecurrence = 5 years and timestart adjuvant chemo-
therapy = 10 weeks). It should also be noted that experiencing a 
certain event can lead to the modification of other event times 
(eg, multiplication of timerecurrence by factor 1.3 after comple-
tion of adjuvant chemotherapy). After all patients have died, 
which terminates the simulation, the quality-adjusted life ex-
pectancy (QALE) of each individual can be reconstructed by 
weighting different periods of the clinical course with health 
state utility values (0: death; 1: perfect health). As an example, 
a patient who had lived 5 years in perfect health and 5 addi-
tional years with bothersome symptoms (utility: 0.7) before 
she finally died would accumulate 5 × 1 + 5 × 0.7 = 8.5 qual-
ity-adjusted life years. By averaging the accumulated QALE 
of each strategy, it is possible to compare two or more strate-
gies such as ERC and different types of novel therapies.
Figure 1 visualizes the logic of our discrete event simula-
tion model. In a first step a cohort of hypothetical patients is 
created. Next, specific characteristics (such as age, sex, and 
tumor type) as well as strategy-independent event times are 
assigned to all individuals before the cohort is cloned four 
times (one clone per strategy; ie, ERC and three types of 
novel therapies). The cloning can not only be regarded as the 
modeling equivalent to randomization in a randomized con-
trolled trial (as it creates strategy arms with identical base-
line characteristics) but also as a means to reduce unwanted 
variance.11,12 After cloning but before the start of the simu-
lation, patients receive strategy-dependent modifications of 
F I G U R E  1  Simulation logic
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characteristics and event times. As soon as the simulation 
clock runs, the simulation logic identifies the first event 
among all individuals (eg, start of radical cystectomy in pa-
tient 12 in 3 days). The simulating clock is then advanced to 
the identified event time (eg, 3 days), the identified patient 
(eg, patient 12) gets an update of certain characteristics (eg, 
age + 3 days), and also experiences the identified event (eg, 
start of radical cystectomy), which might include the mod-
ification of characteristics or event times. After processing 
this event, the simulation logic identifies the next event and 
so on. Individuals that experience the event “death” leave the 
simulation. A detailed description of the full simulation logic 
can be found in the Appendix S1.
2.3 | Model input
Our simulation required different types of input parameters 
such as event times (eg, time to death), probabilities (eg, 
mortality during radical cystectomy), and health state utility 
values (eg, health state utility of receiving perioperative chem-
otherapy) that were mostly obtained through systematic lit-
erature search. Event times were sampled from either Weibull 
distributions, exponential distributions, or uniform distribu-
tions. Life tables provided by the National Center for Health 
Statistics of the United States served as source data to sample 
the background mortality of each patient based on age and 
sex.15 Whenever possible, we used published multivariable re-
gression models16-19 to inform model inputs based on patient 
characteristics, which allowed us to, for example, sample time 
to tumor recurrence after radical cystectomy based on sex, age, 
tumor characteristics, and perioperative chemotherapy. Two 
input parameters (median time to muscle invasion after failure 
of novel therapy and median time to metastatic progression 
after muscle invasion) could not be derived through literature 
review and plausible ranges had to be estimated through ex-
pert opinion (bounded by extrapolations from related but not 
readily comparable literature). To account for the uncertainty 
of these two parameters as well as for the uncertainty associ-
ated with health state utility values, we performed probabilistic 
analyses and therefore replicated the simulation 1000 times, 
each time with a different set of plausible input parameters. A 
detailed list of all input parameters (including the methodol-
ogy used for their derivation) can be found in the Appendix S1.
2.4 | Validation and calibration
The validity of our model was iteratively ascertained dur-
ing the whole research process. Face validity (level of model 
complexity, plausibility of clinical patient trajectories, con-
sistency of outcomes) was verified by involving content 
experts at all stages of development. In addition, the whole 
model was formally debugged several times to detect poten-
tial coding errors and/or inconsistencies. Furthermore, we 
externally validated the simulation output by comparing the 
predicted outcomes with results published in literature (vali-
dation targets). Discrepancies between validation targets and 
model output were addressed by calibrating certain input 
parameters assumed to be influential (calibration input). 
Specifically, this involved repeating the simulation thou-
sands of times while varying the calibration input. The cali-
brated values were then derived by retaining the calibration 
input sets that yielded minimal discrepancy between model 
output and validation targets. In accordance with prior work 
of Vanni et al,20 we included the best fitting values from the 
calibration process in the probabilistic analysis to account for 
the uncertainty associated with them. A detailed description 
of the external validation as well as of the calibration process 
can be found in the Appendix S1.
2.5 | Analysis
To quantitatively verify if the recommendations issued by the 
IBCG and the FDA/AUA reflect clinically meaningful out-
comes from a QALE perspective, we fixed the parameters of 
the time to event distribution reflecting “time to failure novel 
therapy” to values that mirror the efficacy statements “50% at 
6 months, 30% at 12 months, and 25% at 18 months” (IBCG) 
and “40%-50% at 6 months and 30% at 18-24 months” (FDA/
AUA). We therefore used an optimization algorithm (simu-
lated annealing21) to find piece-wise exponential distributions 
that match the above-mentioned value pairs as close as possi-
ble. Since these recommendations do not specify the efficacy 
beyond two years, it was necessary to assume three scenarios 
that we defined as follows: optimistic behavior (ie, treatment 
failure in additional 5% of the patients until year 5, in addi-
tional 1% between 5 years and plateau at 7.5 years), interme-
diate behavior (ie, additional 5% until year 5, additional 5% 
between 5 years and plateau), and pessimistic behavior (ie, ad-
ditional 10% until year 5, additional 5% between 5 years and 
plateau). Furthermore, we explored higher efficacy thresh-
olds by increasing the two recommendations by +5%, +10%, 
and + 15% (each with optimistic, intermediate, and pessimis-
tic behavior after the initial two years of treatment). The re-
sulting 24 failure curves are visualized in the Appendix S1.
To account for all nuances of our research question, the 
final analysis had to involve three simulation levels (ie, lower, 
middle, upper): At the lower level, each of the four strategies 
was simulated among a cohort of 100,000 patients. We ag-
gregated the discounted (3%) QALE of the resulting 400,000 
individuals (4 strategies × 100,000 patients) into strategy-spe-
cific means. Next the incremental benefit of each type of novel 
therapy was defined as the difference between QALENovel 
therapy and QALEERC. We empirically chose a cohort size of 
   | 3291WETTSTEIN ET AL
100,000 patients as this number yielded highly stable results 
with a percentage deviation of less than 1% from the mean 
value. At the middle level, we replicated, as described ear-
lier, each lower-level run 1000 times with probabilistic input 
parameters and aggregated the results into means to reflect 
the uncertainty associated with some input parameters (expert 
opinions, health state utility values, and parameters derived 
through calibration). Last, we simulated at the upper level the 
24 above-mentioned efficacy thresholds. Therefore, reliably 
analyzing 24 efficacy thresholds required simulating the clini-
cal course of 9.6 billion individuals (4 strategies × 100,000 pa-
tients × 1000 probabilistic samples × 24 efficacy thresholds).
3 |  RESULTS
3.1 | Validity of model
After ascertaining face validity with content experts, repeated 
verification, external validation, and calibration we consid-
ered our model valid. Figure 2 visualizes the clinical course 
of 20 random patients that were generated by our simulation 
at an efficacy threshold reflecting an optimistic interpreta-
tion of the IBCG recommendation. The upper 10 patients 
were managed by the strategy “ERC” while the lower 10 
patients received the strategy “Novel therapy.” It can be 
seen that even this simplified visualization of our model has 
enough complexity to account for clinical events such as 
perioperative chemotherapy (patients 6 + 11) and death as a 
complication of radical cystectomy (patients 4 + 14). After 
calibration, external validation of the strategy “ERC” against 
an ERC cohort22 that was not used as input source demon-
strated credible results (simulation output vs external source) 
regarding pT3/pT4 disease at ERC (15.4% vs 13%), positive 
nodal disease at ERC (13.2% vs 13%), and cancer-specific 
survival (86.6% vs 85% at 5 years, 76.4% vs 76% at 10 years).
3.2 | Required efficacy of novel therapies
We visualized the incremental benefit of the novel therapies 
“systemic,” “low-intensity intravesical,” and “high-intensity 
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intravesical” over the reference strategy “ERC” at differ-
ent efficacy thresholds in Figures 3-5 respectively. Both the 
original IBCG recommendation and the original FDA/AUA 
recommendation rarely showed an incremental benefit of the 
novel therapies over ERC. Especially when looking at an op-
timistic interpretation of the IBCG recommendation, it can 
be seen that only 2.4%, 5.6%, and 5.1% of all probabilistic 
samples favor the novel therapies “systemic, “low-intensity 
intravesical,” and high-intensity intravesical,” respectively. 
Although an optimistic interpretation of the FDA/AUA rec-
ommendation yields considerably better results of 16.0%, 
27.0%, and 25.7% of simulations, the resulting means are still 
below the line of indifference.
To find a valid recommendation at which a novel ther-
apy can compete with ERC from a QALE perspective, it 
is necessary to identify an efficacy threshold at which the 
probabilistic results evenly spread around a mean of zero 
with ideally 50% of all sets favoring the novel therapy. When 
looking at variations of the IBCG recommendation, the point 
of indifference is reached, regardless of the specific type of 
novel therapy, between +10% and 15% (optimistic), at 15% 
(intermediate), and much higher than 15% (pessimistic). 
Replicating this approach among variations of the FDA/AUA 
recommendation, indifference is achieved, again regardless 
of the specific type of novel therapy, at 5% (optimistic), 10% 
(intermediate), and 15% (pessimistic).
4 |  DISCUSSION
In this simulation study, we quantitatively verified if current 
recommendations regarding clinically meaningful outcomes 
in single-arm trials evaluating novel therapies in BCG-
unresponsive NMIBC translate into meaningful outcomes 
from an integrative healthcare perspective. We therefore com-
pared three different types of novel therapies against ERC as 
the standard of care. Our work not only showed that there is 
a low probability that the recommendation of the IBCG (50% 
F I G U R E  3  Incremental benefit of novel therapy (systemic) over early radical cystectomy [quality-adjusted life years, discounted at 3%]. 
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at 6 months, 30% at 12 months, and 25% at 18 months) or 
the one of the FDA/AUA (40%-50% at 6 months and 30% at 
18-24 months) would make any novel therapies a real com-
petitor to ERC but also that these recommendations need to 
be increased by at least 10% (IBCG) and 5% (FDA/AUA). 
Thus, we feel that an appropriate recommendation should 
suggest an efficacy threshold of at the minimum 45%-55% at 
6 months and 35% at 18-24 months (complete response rate/
recurrence-free survival).
Effective novel therapies for BCG-unresponsive NMIBC 
are desperately needed. Clinician-scientists and companies 
embarking on those single arm phase II registration trials 
therefore need guidance regarding appropriate designs and 
clinically meaningful outcomes. Since there is a low proba-
bility that the current recommendations translate into com-
petitive outcomes, meaning that the novel therapy will yield 
on average the same amount or even more quality-adjusted 
life years than ERC, there is also a low probability that the 
resulting innovation will be cost-effective. Hence, to prevent 
the development of cost-ineffective novel therapies, it is of 
high importance to increase these recommendations to levels 
where novel therapies yield at least a QALE comparable to 
ERC. It should be noted, however, that although our simula-
tion recommends a clinically meaningful efficacy threshold 
for such single-arm trials, it does not inform on sample sizes 
that would be required to yield acceptable statistical reliabil-
ity of the efficacy estimate.
In January 2020, the FDA approved pembrolizumab, a 
monoclonal antibody targeting the programmed cell death 
protein 1 (PD-1), for the treatment of patients with BCG-
unresponsive, high-risk, NMIBC with CIS with or without 
papillary disease who are ineligible for or have elected not to 
undergo ERC.23 The decision was largely based on interim 
results (N = 96; cohort A) of the KEYNOTE-057 study, a sin-
gle-arm phase II trial, that demonstrated a complete response 
rate of 41% (95% confidence interval: 31%-51%) and a com-
plete response duration over one year in 20% of all patients.24 
Although the investigators used a slightly different outcome 
F I G U R E  4  Incremental benefit of novel therapy (low-intensity intravesical) over early radical cystectomy [quality-adjusted life years, 
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measure, it is evident that the current KEYNOTE-057 re-
sults do not meet our proposed efficacy thresholds and that 
their clinical meaningfulness has to be doubted. The FDA’s 
9:4 vote in favor of pembrolizumab23 despite unclear clin-
ical meaningfulness was probably mostly driven by the 
unmet clinical need and the fact that pembrolizumab outper-
formed prior less successful NTs such as valrubicin by far.25 
Furthermore, the approval has to be interpreted also in the 
light of the developments during the last two decades: As in-
vestigated by Tibau et al, the FDA approved 27 cancer drugs 
between 2006 and 2016 based on single-arm trials although 
only a minority of them (7.4%) met the threshold for substan-
tial clinical benefit as measured by the European Society for 
Medical Oncology Magnitude of Clinical Benefit Scale.26,27
This study is novel as it leverages the power of a deci-
sion-analytic approach by using the infrastructure of a super-
computer. This allowed us to not only investigate 24 different 
efficacy thresholds, but also to explore the uncertainty asso-
ciated with each threshold by 1000 probabilistic input sets. At 
the same time, we were able to simulate 400,000 patients per 
probabilistic run which yielded highly stable results. Such a 
powerful approach would not have been feasible in the setting 
of a personal computer.
Nevertheless, our work has an important limitation: It is 
at the end of the day a simulation of hypothetical patients and 
might therefore be suspiciously regarded as a “black box.” 
We tried to mitigate this suspicion at several levels. First, 
we extensively ascertained the validity of our model which 
included, besides other steps, calibration against data from 
the literature. Second, we explored uncertainty using 1000 
probabilistic input sets per threshold. Lastly, we tried to pro-
vide full transparency by making the model documentation 
readily available in the Appendix S1.
This simulation study demonstrated that the current rec-
ommendations regarding clinically meaningful outcomes for 
single-arm phase II registration trials evaluating the efficacy 
of novel therapies in BCG-unresponsive NMIBC are too low. 
There is a high probability that novel therapies with an efficacy 
F I G U R E  5  Incremental benefit of novel therapy (high-intensity intravesical) over early radical cystectomy [quality-adjusted life years, 
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as low as specified by the IBCG and FDA/AUA cannot com-
pete with the ERC and therefore will never be clinically effi-
cient from an integrated healthcare perspective. Based on our 
quantitative approach, we propose increasing these thresholds 
to at least 45%-55% at 6  months and 35% at 18-24  months 
(complete response rate/recurrence-free survival) to promote 
the development of clinically truly meaningful novel therapies.
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